US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% SNDK $1,704.16 ▼-0.92%
FinancialContent

Cybin Inc. Common Shares (NY:CYBN)

8.280 UNCHANGED
Last Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
41 42 Next >
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
News headline image
Analyst Expectations for Cybin's Future ↗
 
Via Benzinga
News headline image
Cybin: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials ↗
Cybin One Steps Away From Complete Dosing 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Significant Milestone in Advancing CYB003 Towards Pivotal Studies
Via Investor Brand Network
News headline image
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
News headline image
A Quantum Leap In Psychedelic Research: Study Shows Real-Time Brain Changes After Ketamine Use ↗
A newly published study shows that Kernel’s Flow technology system is in fact able to capture and analyze brain changes following the administration of a psychoactive substance. 
Via Benzinga
News headline image
Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Results from ‘Groundbreaking’ Sponsored Study Measuring Psychedelic Effects
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Results from ‘Groundbreaking’ Sponsored Study Measuring Psychedelic Effects
Via Investor Brand Network
News headline image
Kernel's Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects
From Kernel
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Shares Plans to Develop Scalable Psychedelic Facilitation Training Program
Via Investor Brand Network
News headline image
Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT
From Cybin Inc.
Via Business Wire
News headline image
Why Caribou Biosciences Shares Are Trading Higher By Around 58%? Here Are Other Stocks Moving In Thursday's Session ↗
Gainers Caribou Biosciences, Inc. (NASDAQ: CRBU) shares jumped 58.1% to $6.45 after the company announced a $25 million equity investment from Pfizer. 
Via Benzinga
News headline image
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More ↗
World's Largest Psychedelics Conference Boasts 12K Attendees 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Names New COO, Announces Participation in Upcoming London Symposium
Via Investor Brand Network
News headline image
Cybin to Participate in PSYCH Symposium London 2023
From Cybin Inc.
Via Business Wire
News headline image
Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer
From Cybin Inc.
Via Business Wire
News headline image
Cybin's FY2023 Financials, Guidance And Appointment Of Sanford R. Climan As Strategic Advisor ↗
Psychedelics biopharma company Cybin Inc. (NYSE: CYBN) shared its financial results for the fiscal year ended this March 31 as well as recent business highlights. Numbers show: Total cash of $12.5... 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases FY 2023 Financial Report, Business Highlights
Via Investor Brand Network
News headline image
Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Names Seasoned Veteran as Strategic Advisor
Via Investor Brand Network
News headline image
Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Participate at Psychedelic Science 2023 Conference
Via Investor Brand Network
News headline image
Cybin to Participate in the 2023 MAPS Psychedelic Science Conference
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Participate at Upcoming H.C. Wainwright Neuropsychiatry Conference
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Report on Status of Capital, Product Development
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin Inc. Provides Corporate Update
From Cybin Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 69 stocks hit new 52-week lows. 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
41 42 Next >